DYN

Dyne Therapeutics Inc

NASDAQ: DYN · HEALTHCARE · BIOTECHNOLOGY

$16.98

+0.24% today

Updated 2026-10-28

Market cap

$2.66B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.30

Dividend yield

—

52W range

$14 – $27

Volume

3.0M

Market cap

$2.66B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.30

Dividend yield

—

52W range

$14 – $27

Volume

3.0M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

6.7

Valuation

3/9

Piotroski F-Score

Weak

0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →271 stocks currently score above 75

Price targets

Analyst target

$35.73

+110.42%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy13 Buy0 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 0.93 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-131.80M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-165.24M	$-235.94M	$-317.42M	$-446.21M	$-178.56M
EPS	—	—	—	—	$-3.30
Free cash flow	$-156.71M	$-188.89M	$-294.75M	$-405.13M	$-131.80M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DYN	$2.66B	37	4.3	3.0	6.7	6.5	—	Hold
LLY	$1.12T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$615.87B	57	4.7	8.5	2.7	5.5	-83.05%	Buy
ABBV	$504.37B	73	6.7	8.5	4.0	5.0	-86.73%	Strong Buy
UNH	$360.32B	62	6.7	6.0	4.7	5.5	-25.92%	Buy
MRK	$360.08B	36	4.0	4.5	2.0	5.0	-73.68%	Hold

Smart narrative

Dyne Therapeutics Inc trades at $16.98. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.93, it sits in the distress.

Frequently asked questions

What is Dyne Therapeutics Inc's stock price?

Dyne Therapeutics Inc (DYN) trades at $16.98.

Is Dyne Therapeutics Inc overvalued?

Dyne Therapeutics Inc carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Dyne Therapeutics Inc (DYN)?

The 12-month analyst consensus target is $35.73, about 110.4% above the current $16.98. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Dyne Therapeutics Inc's Altman Z-Score is 0.93, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-58.90%

Beta1.12

50D MA$20.53

200D MA$19.41

Shares out0.19B

Float0.19B

Short ratio—

Avg volume3.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DYN vs LLY →DYN vs JNJ →DYN vs ABBV →Stock screener →